Prasugrel
![](/Images/godic/202502/04/Prasugrel_racemic.svg1256.png")
![](/Images/godic/202502/04/Prasugrel1256.png")
![The reaction of prasugrel (top left) to its active metabolite (R-138727, top right). Unlike the related drug clopidogrel, prasugrel activation does not involve oxidation by the enzyme CYP2C19, as the relevant oxygen (at the thiophene ring) is already present in the prodrug. Instead, both the first and last steps are hydrolyses. The two structures at the bottom represent the inactive thiolactone; they are tautomers of each other.](/Images/godic/202502/04/Prasugrel_activation.svg1256.png")
Prasugrel (trade name Effient in the US and India, and Efient in the EU) is a pharmaceutical drug that acts as a platelet inhibitor and is used to prevent thrombosis (blood clotting). It was developed by Daiichi Sankyo Co. and produced by Ube and currently marketed in the United States in cooperation with Eli Lilly and Company.